John Klein functions as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. In addition to his pursuits with Cambridge Therapeutics, John Klein serves as a member of the Board of Trustees of Hackensack Meridian Health Hospitals and keeps apprised of developments in the state of health care in his region through various news outlets.
In April 2019, NJSpotlight’s online “Healthcare” section summarized a major new report on the health care landscape in New Jersey that additionally offered insights into the best ways for the state’s policymakers to improve the quality and equitable delivery of medical care.
Entitled “Building a Culture of Health,” this report was created with support from the Robert Wood Johnson Foundation and Rutgers University.
It notes that, despite New Jersey’s advances in providing strong family leave programs for workers, high-quality early childhood education, and public education campaigns that have helped reduce smoking rates, a disturbing number of disparities in health care distribution remain across ethnicity, income, geography, and social class. The report estimates that close to 6,500 people die needlessly in the state every year due to such barriers to access.
The report consists of more than one dozen specific recommendations to officials planning health care policy, urging them to fund targeted improvements. The first item on the list involves upgrading the quality of maternal and infant care. Others given high priority include strengthening overall community health by ensuring that at-risk families can access quality housing, education, and paid family leave benefits.
With more than three decades of experience as a healthcare and pharmaceutical executive, John Klein functions as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. During his six-year service as the CEO of Cambridge Therapeutics, John Klein developed knowledge of the Food and Drug Administration’s Code of Federal Regulations, as well as rules enacted by the State of New Jersey.
The New Jersey Department of Human Services (NJDHS) continues to make changes to state policy to ensure Medicaid patients have access to effective therapies for substance-abuse disorders. As of March 31, 2019, the state’s 1.7 million Medicaid enrollees are no longer required to gain approval from the managed-care plan that administers their insurance benefits before receiving medication-assisted treatment (MAT) for opiate addiction.
Viewed as the gold-standard for addressing opiate dependency, MAT involves prescribing patients opioid-replacement medications to minimize withdrawal symptoms and help calm addictive behaviors. In addition to assisting to eliminate insurance hurdles for state Medicaid enrollees, the NJDHS released new rules mandating all addiction-treatment facilities with such patients to offer MAT as a treatment option, effective July 1, 2019.
A distinguished pharmaceutical executive, John Klein serves as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. Also the former CEO of Cambridge Therapeutics, John Klein keeps up with healthcare industry news in his state.
In April 2019, New Jersey health officials released a statement recommending a large increase in the number of medical-marijuana dispensaries to meet the state’s rapidly-expanding demand. Currently, New Jersey has only six dispensaries, called Alternative Treatment Centers, but health officials estimate the state will need to grow its capacity to 50 to 90 dispensaries over three years to keep pace with the rising number of people using medicinal marijuana.
With approximately 100 new medical-marijuana patients per day, the mounting demand is partly driven by Governor Phil Murphy’s recent move to approve new conditions for treatment with medical marijuana, including chronic pain, end-stage cancer, post-traumatic stress disorder, and opioid use disorder. The number of physicians prescribing through the state’s medicinal-marijuana program also has grown by about 40 percent since January 2018, when Governor Murphy took office.
Drawing on his extensive background in the healthcare and pharmaceutical industries, John Klein serves as the chairman of Cambridge Therapeutics. Aside from providing strategic direction to Cambridge Therapeutics, John Klein serves as a trustee for New Jersey’s Hackensack Meridian Health network.
New Jersey officials recently have undertaken several initiatives to improve mental health care in the state. For instance, Hackensack Meridian Health, a network of 16 hospitals and hundreds of outpatient physician offices, has formed a new partnership with Carrier Clinic, a long-standing addiction-treatment agency, to provide integrated behavioral healthcare for its patients.
In addition, the state is working to make it easier for children with emotional and behavioral issues to receive appropriate health care. New Jersey has developed nine regional hospital-based programs that connect pediatricians with behavioral-health providers for advice on diagnoses and treatment. With new funding from the U.S. Department of Health and Human Services and The Nicholson Foundation, the state plans to invest an additional $2.3 million into programs that integrate pediatric behavioral health.